Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1840 studies found for:    new vaccines
Show Display Options
Rank Status Study
1 Completed Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)
Conditions: HDL;   Drug Safety
Intervention: Biological: ATH03
2 Active, not recruiting MenPF-1 - A New Vaccine Against Meningococcal Disease
Condition: Serogroup B Meningococcal Disease
Intervention: Biological: MenPF-1.
3 Recruiting Complement 2: Blood Donations to Develop Vaccines Against Infectious Diseases
Condition: Complement Mediated Bacterial Killing in Healthy Adults
4 Completed RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections.
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: PanAd3-RSV given intra-nasally (high dose);   Biological: MVA-RSV given by intra-muscular injection (high dose);   Biological: PanAd3-RSV given by intra-muscular injection (high dose);   Biological: PanAd3-RSV given intranasally (low dose);   Biological: MVA-RSV given by intra-muscular injection (low dose);   Biological: PanAd3-RSV given by intra-muscular injection (low dose)
5 Completed An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84
Condition: Clostridium Difficile Infection
Intervention: Biological: IC84
6 Recruiting Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis
Conditions: Pneumococcal Infection;   ANCA-associated Vasculitis
7 Active, not recruiting Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
Condition: Melanoma
Intervention: Biological: Immunotherapeutic GSK2302025A, different formulations
8 Completed Open-Label Study Assessing The Safety, Immunogenicity and Dose Response of IC47
Condition: Pneumococcal Infections
Intervention: Biological: IC47
9 Withdrawn Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients
Condition: Parkinson's Disease
Interventions: Biological: AFFITOPE® PD01A + Adjuvant;   Biological: Adjuvant without active component
10 Completed
Has Results
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
Condition: Meningococcal Vaccine
Interventions: Biological: rLP2086;   Biological: Havrix (HAV);   Biological: Saline
11 Completed
Has Results
A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.
Condition: Healthy
Interventions: Biological: rLP2086;   Other: Placebo
12 Active, not recruiting A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years
Interventions: Biological: Bivalent rLP2086 Vaccine;   Biological: Licensed pediatric hepatits A vaccine;   Other: Normal Saline
13 Completed Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects
Condition: Infections, Meningococcal
Intervention: Biological: Meningococcal vaccine GSK134612
14 Completed A Study of the Safety and Effectiveness of Two New Malaria Vaccines
Condition: Malaria
Interventions: Biological: AdCh63-MSP1 (lower dose) vaccine and MVA-MSP1 vaccine;   Biological: AdCh63-MSP1 vaccine (higher dose) and MVA-MSP1 vaccine followed by challenge
15 Completed TY800 Dose Escalation (Typhoid)
Condition: Typhoid and Paratyphoid Fevers
Interventions: Biological: Ty800;   Drug: Placebo
16 Completed Immunogenicity of SA 14-14-2 JE Vaccine
Condition: Healthy Infants 10 - 12 Months of Age.
Interventions: Biological: JE Vaccine existing facility;   Biological: JE vaccine new plant lot 1;   Biological: JE vaccine new plant lot 2;   Biological: JE vaccine new plant lot 3
17 Active, not recruiting VRC 208: Dose, Safety and Immunogenicity of a Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine, VRC-EBOMVA079-00-VP (MVA-EbolaZ), Administered Alone or as a Boost to cAd3-Ebola Vaccines in Healthy Adults
Condition: Healthy Adult Immune Responses to Vaccine
Interventions: Biological: VRC-EBOMVA079-00-VP (MVA-EbolaZ);   Biological: VRC-EBOADC069-00-VP (cAd3-EBO)
18 Completed Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study
Condition: Dermatitis, Atopic
Interventions: Biological: Fluzone® Intradermal Vaccine;   Biological: Fluzone® (Intramuscular) vaccine
19 Completed Low-dose Challenge Model With Enterotoxigenic E Coli
Condition: Diarrhea
Interventions: Biological: E coli strain H10407 and buffer;   Biological: E coli H10407 and buffer
20 Completed
Has Results
Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination
Condition: Smallpox
Interventions: Biological: Vaccinia virus: ACAM2000 smallpox vaccine;   Biological: vaccinia virus (calf lymph): Dryvax

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years